GSK to acquire Nuvalent in merger agreement dated June 9, 2026

GlaxoSmithKline LLC agreed to acquire Nuvalent, Inc. through a merger with subsidiary Harmony Row Acquisition Co., with terms outlined in an executed agreement and plan of merger. The transaction represents a significant consolidation in the pharmaceutical sector, combining GSK's established operations with Nuvalent's pipeline.